📊 OTLC Key Takeaways
Is Oncotelic Therapeutics, Inc. (OTLC) a Good Investment?
Oncotelic faces severe financial distress with revenue collapsed 96% YoY to $70K, operating losses of $658K, and critically low liquidity (0.08x current ratio) on only $409K cash. With negative operating cash flow of $600K annually, the company has less than one year of cash runway, posing significant going concern risk.
Why Buy Oncotelic Therapeutics, Inc. Stock? OTLC Key Strengths
- Slight improvement in net loss magnitude YoY (minor positive momentum in loss trajectory)
- Debt-to-equity ratio of 0.14x is not highly leveraged
- Retains $28.2M in total assets providing some buffer
OTLC Stock Risks: Oncotelic Therapeutics, Inc. Investment Risks
- Revenue collapsed 96% YoY indicating loss of commercial viability and market acceptance
- Critically low liquidity (0.08x current ratio) indicating imminent cash crisis and inability to meet short-term obligations
- Negative $613K free cash flow with only $409K cash remaining suggests sub-one-year runway before insolvency
- Deeply negative operating margins (-940%) and net margins (-1526%) with no clear profitability path
- Potential going concern failure requiring debt restructuring or capital infusion
- Minimal insider activity (1 Form 4 filing in 90 days) suggests lack of management confidence
Key Metrics to Watch
- Monthly cash burn rate and total runway to depletion
- Quarterly revenue stabilization or further deterioration
- Capital raise announcements, debt restructuring, or asset liquidation events
Oncotelic Therapeutics, Inc. (OTLC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OTLC Profit Margin, ROE & Profitability Analysis
OTLC vs Healthcare Sector: How Oncotelic Therapeutics, Inc. Compares
How Oncotelic Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oncotelic Therapeutics, Inc. Stock Overvalued? OTLC Valuation Analysis 2026
Based on fundamental analysis, Oncotelic Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oncotelic Therapeutics, Inc. Balance Sheet: OTLC Debt, Cash & Liquidity
OTLC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oncotelic Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.01 reflects profitable operations.
OTLC Revenue Growth, EPS Growth & YoY Performance
OTLC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $70.0K | $115.3K | $0.00 |
| Q3 2023 | $70.0K | $115.3K | $0.00 |
| Q3 2021 | $1.7M | -$1.6M | N/A |
| Q2 2021 | $1.4M | $582.1K | $0.01 |
| Q1 2021 | $340.9K | -$2.8M | N/A |
| Q3 2020 | $1.7M | $582.1K | N/A |
| Q2 2020 | $1.4M | $582.1K | $0.01 |
| Q1 2020 | $340.9K | -$976.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oncotelic Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
OTLC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oncotelic Therapeutics, Inc. (CIK: 0000908259)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OTLC
What is the AI rating for OTLC?
Oncotelic Therapeutics, Inc. (OTLC) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OTLC's key strengths?
Claude: Slight improvement in net loss magnitude YoY (minor positive momentum in loss trajectory). Debt-to-equity ratio of 0.14x is not highly leveraged.
What are the risks of investing in OTLC?
Claude: Revenue collapsed 96% YoY indicating loss of commercial viability and market acceptance. Critically low liquidity (0.08x current ratio) indicating imminent cash crisis and inability to meet short-term obligations.
What is OTLC's revenue and growth?
Oncotelic Therapeutics, Inc. reported revenue of $70.0K.
Does OTLC pay dividends?
Oncotelic Therapeutics, Inc. does not currently pay dividends.
Where can I find OTLC SEC filings?
Official SEC filings for Oncotelic Therapeutics, Inc. (CIK: 0000908259) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OTLC's EPS?
Oncotelic Therapeutics, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OTLC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Oncotelic Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OTLC stock overvalued or undervalued?
Valuation metrics for OTLC: ROE of -11.8% (sector avg: 15%), net margin of -1,526.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OTLC stock in 2026?
Our dual AI analysis gives Oncotelic Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OTLC's free cash flow?
Oncotelic Therapeutics, Inc.'s operating cash flow is $-600.1K, with capital expenditures of $13.0K. FCF margin is -875.9%.
How does OTLC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,526.0% (avg: 12%), ROE -11.8% (avg: 15%), current ratio 0.08 (avg: 2).